GRM4 gene polymorphism is associated with susceptibility and prognosis of osteosarcoma in a Chinese Han population

Osteosarcoma (OS), the most common primary bone malignancy, occurs primarily in adolescents and young adults. In earlier genome-wide association studies, rs7591996, rs10208273, rs17206779 and rs1906953 were identified as candidate loci for OS in Caucasians but the association of these single-nucleotide polymorphisms (SNPs) with OS in a Chinese Han population remains unknown. We measured the frequency of these four variants in a Chinese Han population to better understand the genetic etiology of OS. Polymerase chain reaction sequencing was used to detect the genotypes of four candidate SNPs in peripheral blood samples collected from 168 OS patients and 216 healthy controls. Logistic regression models were used to estimate the odds ratios and 95 % confidence intervals. We found rs1906953 in the glutamate receptor metabotropic 4 (GRM4) gene was associated significantly with OS in our Chinese Han population; as with the other SNPs, however, no statistically significant difference was detected. Further analysis showed the association between rs1906953 and OS was independent of gender and age. The rs1906953 locus was not associated with Enneking stages or tumor location; however, it was associated significantly with OS metastasis and prognosis. The GRM4 gene polymorphism was associated with the susceptibility and metastasis of OS in a Chinese Han population.

[1]  Ego Seeman,et al.  Bone remodelling: its local regulation and the emergence of bone fragility. , 2008, Best practice & research. Clinical endocrinology & metabolism.

[2]  W. Wallace,et al.  Twentieth-century survival from osteosarcoma in childhood. Trends from 1933 to 2004. , 2007, The Journal of bone and joint surgery. British volume.

[3]  M. Pearce,et al.  Stature of young people with malignant bone tumors , 2004, Pediatric blood & cancer.

[4]  D. Benayahu,et al.  Cellular and molecular properties associated with osteosarcoma cells , 2001, Journal of cellular biochemistry.

[5]  Silke Szymczak,et al.  Genetics and Beyond – The Transcriptome of Human Monocytes and Disease Susceptibility , 2010, PloS one.

[6]  A. Patiño-García,et al.  Analysis of the human tumour necrosis factor-alpha (TNFα) gene promoter polymorphisms in children with bone cancer , 2000, Journal of medical genetics.

[7]  Zhiming He,et al.  Lysyl Oxidase Polymorphisms and Susceptibility to Osteosarcoma , 2012, PloS one.

[8]  R. Hu,et al.  Regulation of γ-aminobutyric acid (GABA) release in cerebral cortex in the γ-hydroxybutyric acid (GHB) model of absence seizures in rat , 2000, Neuropharmacology.

[9]  Seung-Yong Jeong,et al.  Metabotropic Glutamate Receptor 4 Expression in Colorectal Carcinoma and Its Prognostic Significance , 2005, Clinical Cancer Research.

[10]  R. Hayes,et al.  Genetic variation at chromosome 8q24 in osteosarcoma cases and controls. , 2010, Carcinogenesis.

[11]  R. Kurzrock,et al.  Phase 1 clinical trials for sarcomas: the cutting edge , 2011, Current opinion in oncology.

[12]  Q. Wei,et al.  Exploratory Analysis of Fas Gene Polymorphisms in Pediatric Osteosarcoma Patients , 2007, Journal of pediatric hematology/oncology.

[13]  William Stafford Noble,et al.  Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project , 2007, Nature.

[14]  G. Ottaviani,et al.  The epidemiology of osteosarcoma. , 2009, Cancer treatment and research.

[15]  W. Rzeski,et al.  Expression of glutamate receptor subunits in human cancers , 2009, Histochemistry and Cell Biology.

[16]  A. Buckley,et al.  Sulfasalazine‐induced cystine starvation: Potential use for prostate cancer therapy , 2007, The Prostate.

[17]  R. Gorlick Current concepts on the molecular biology of osteosarcoma. , 2010, Cancer treatment and research.

[18]  E. Kleinerman,et al.  Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine. , 2010, Journal of aerosol medicine and pulmonary drug delivery.

[19]  M. Joyce,et al.  Bone sarcomas: Overview of management, with a focus on surgical treatment considerations , 2010, Cleveland Clinic Journal of Medicine.

[20]  G. Schackert,et al.  Glutamate receptors in pediatric tumors of the central nervous system , 2010, Cancer biology & therapy.

[21]  E. Hinoi,et al.  Glutamate signaling system in bone. , 2004, Journal of pharmacological sciences.

[22]  Jinmin Zhao,et al.  PIK3CA and AKT gene polymorphisms in susceptibility to osteosarcoma in a Chinese population. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[23]  L. Liang,et al.  A genome-wide association study of global gene expression , 2007, Nature Genetics.

[24]  S. Chanock,et al.  Analysis of Genes Critical for Growth Regulation Identifies Insulin-like Growth Factor 2 Receptor Variations with Possible Functional Significance as Risk Factors for Osteosarcoma , 2007, Cancer Epidemiology Biomarkers & Prevention.

[25]  R. Hayes,et al.  A comprehensive candidate gene approach identifies genetic variation associated with osteosarcoma , 2011, BMC Cancer.

[26]  F. Baas,et al.  Identification of Novel Candidate Oncogenes in Chromosome Region 17p11.2-p12 in Human Osteosarcoma , 2012, PloS one.

[27]  A. Patiño-García,et al.  Analysis of Polymorphisms of the Vitamin D Receptor, Estrogen Receptor, and Collagen I&agr;1 Genes and Their Relationship With Height in Children With Bone Cancer , 2003, Journal of pediatric hematology/oncology.

[28]  P. Picci,et al.  Effect of TP53 Arg72Pro and MDM2 SNP309 Polymorphisms on the Risk of High-Grade Osteosarcoma Development and Survival , 2009, Clinical Cancer Research.

[29]  T. Triche,et al.  Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice. , 2010, The Journal of clinical investigation.

[30]  Jinmin Zhao,et al.  Association of ITGA3 gene polymorphisms with susceptibility and clinicopathological characteristics of osteosarcoma , 2014, Medical Oncology.

[31]  R. Hoover,et al.  Height at diagnosis and birth-weight as risk factors for osteosarcoma , 2011, Cancer Causes & Control.

[32]  S. Chanock,et al.  Germ‐line genetic variation of TP53 in osteosarcoma , 2007, Pediatric blood & cancer.

[33]  P. Genever,et al.  Glutamate signalling in non-neuronal tissues. , 2001, Trends in pharmacological sciences.

[34]  T. Takano,et al.  Beyond the role of glutamate as a neurotransmitter , 2002, Nature Reviews Neuroscience.

[35]  David M. Thomas,et al.  Genome-wide Association Study Identifies Two Susceptibility Loci for Osteosarcoma , 2013, Nature Genetics.

[36]  F. Vannberg,et al.  GENETICS OF GENE EXPRESSION IN PRIMARY IMMUNE CELLS IDENTIFIES CELL-SPECIFIC MASTER REGULATORS AND ROLES OF HLA ALLELES , 2012, Nature Genetics.

[37]  L. Mirabello,et al.  Using Epidemiology and Genomics to Understand Osteosarcoma Etiology , 2011, Sarcoma.

[38]  Gurmit Singh,et al.  Cancer cells release glutamate via the cystine/glutamate antiporter. , 2010, Biochemical and biophysical research communications.

[39]  G. Bacci,et al.  Height as a risk factor in osteosarcoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  M. Koutsilieris,et al.  Characterization of the glutametergic system in MG-63 osteoblast-like osteosarcoma cells. , 2004, Anticancer research.

[41]  S. Bornstein,et al.  A transgenic mouse bearing an antisense construct of regulatory subunit type 1A of protein kinase A develops endocrine and other tumours: comparison with Carney complex and other PRKAR1A induced lesions , 2004, Journal of Medical Genetics.

[42]  O. Snead,et al.  Presynaptic gamma-hydroxybutyric acid (GHB) and gamma-aminobutyric acidB (GABAB) receptor-mediated release of GABA and glutamate (GLU) in rat thalamic ventrobasal nucleus (VB): a possible mechanism for the generation of absence-like seizures induced by GHB. , 1995, The Journal of pharmacology and experimental therapeutics.

[43]  A. Temme,et al.  Silencing of selected glutamate receptor subunits modulates cancer growth. , 2011, Anticancer research.

[44]  L. Mirabello,et al.  Osteosarcoma incidence and survival rates from 1973 to 2004 , 2009, Cancer.

[45]  T. Ueshima,et al.  Glutamate signaling in peripheral tissues. , 2003, European journal of biochemistry.

[46]  Yong Zhang,et al.  Association between TGFBR1*6A and osteosarcoma: A Chinese case-control study , 2010, BMC Cancer.

[47]  Zhaohui S. Qin,et al.  A second generation human haplotype map of over 3.1 million SNPs , 2007, Nature.